Wellington Management Group LLP Has $6.76 Million Stock Position in Enliven Therapeutics, Inc. $ELVN

Key Points

• Wellington Management reduced its Enliven Therapeutics stake by 11.3% in the second quarter, selling 16,983 shares and retaining 133,143 shares valued at approximately $6.76 million. Institutional investors and hedge funds collectively own 95.08% of ELVN.
• Analyst sentiment remains favorable, with eight Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and a $75 price target. Mizuho, Stifel Nicolaus, and HC Wainwright recently raised their price targets.
• ELVN opened at $59.37 and has climbed substantially from its one-year low of $14.78, but the company missed its latest earnings estimate, reporting a quarterly loss of $0.49 per share versus the expected $0.39 loss. Insiders also sold nearly $11 million in shares during the last quarter.

Wellington Management Group LLP lessened its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 11.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 133,143 shares of the company's stock after selling 16,983 shares during the quarter. Wellington Management Group LLP owned 0.18% of Enliven Therapeutics worth $6,757,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company's stock worth $428,000 after purchasing an additional 1,693 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Enliven Therapeutics by 61.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock worth $4,167,000 after purchasing an additional 80,506 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $578,000. Legal & General Group Plc grew its position in shares of Enliven Therapeutics by 52.2% during the 2nd quarter. Legal & General Group Plc now owns 32,225 shares of the company's stock worth $646,000 after purchasing an additional 11,058 shares in the last quarter. Finally, Quantbot Technologies LP increased its holdings in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock worth $90,000 after purchasing an additional 1,434 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ELVN shares. Mizuho boosted their price target on Enliven Therapeutics from $62.00 to $73.00 and gave the company an "outperform" rating in a research note on Tuesday, August 18th. William Blair started coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They set an "outperform" rating on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Stifel Nicolaus upped their target price on Enliven Therapeutics from $80.00 to $82.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Finally, HC Wainwright increased their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a report on Thursday, July 9th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Enliven Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $75.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $59.37 on Wednesday. The company's 50 day simple moving average is $56.00 and its 200 day simple moving average is $44.77. The stock has a market capitalization of $4.35 billion, a price-to-earnings ratio of -35.55 and a beta of 0.30. Enliven Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.69 EPS for the current fiscal year.

Insider Activity

In related news, Director Mika K. Derynck sold 158,795 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director directly owned 87,373 shares in the company, valued at $5,260,728.33. This represents a 64.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $58.58, for a total value of $352,534.44. Following the completion of the sale, the chief financial officer owned 40,036 shares in the company, valued at $2,345,308.88. This trade represents a 13.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 186,849 shares of company stock valued at $10,998,857 over the last quarter. 3.00% of the stock is owned by company insiders.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.